GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
GAiT wishes to express our condolences to @Simon_H_Ellison's family after he passed today after a brave fight with cancer.
ISCT2020, initially planned as a traditional conference in Paris, will now be held as virtual meeting instead on the same dates.
ISCT transitions to a virtual conference amidst coronavirus concerns
The International Society for Cell and Gene Therapy (ISCT; BC, Canada) has decided to alter their globally attended conference (27–30 May 2020, Pari...
GAiT employees are working from home because of the COVID-19 outbreak but are still contactable through the usual numbers and emails.
GAiT had planned to hold a Quality Workshop to dovetail ISCT2020 in Paris this year. Because of the COVID-19 epidemic, this will now be delayed until later in the year.
New infographic on @RegMedNet detailing quality control guidelines for clinical iPSCs. Check it out here: http://bit.ly/32SyScc
Regenerative Medicine's infographic showing recommended standards for clinical grade iPSCs for therapeutic development is now online:
Minimum standards for clinical iPSCs: what the experts suggest
In this infographic, we summarize key clinical standards suggested by the experts involved in the GAiT global banking network, as described in their R...
Scripting of the Quality Round manuscript is ongoing but has been delayed by the Corona virus outbreak. Thank you for your patience and once the manuscript is prepared, it will be circulated to Participants for comment/input.
GAiT Chairperson Prof Marc Turner will be speaking on GAiT activity in London 30th March - 1st April at the Terrapin 'Advanced Therapies Congress and Expo'
Research. Develop. Collaborate. Commercialise | Advanced Therapies
The global marketplace for investment, commercial opportunities and collaboration in the advanced therapies and regenerative medicine space.
A report released by the @CGTCatapult states that employment in the UK cell and gene therapy industry is set to double by 2024 the report indicates there are concerns over how demand will be met; primarily, the availability of targeted academic courses
Demand for ‘specialist skills’ in UK cell and gene therapy, says report
A skills demand report stated that employment in the UK cell and gene therapy industry is expected to double by 2024, with support of targeted courses...
GAiT will be speaking at the 'Translation and Innovation in induced Pluripotent Stem Cell Science' Workshop at Saïd Business School, Oxford on the 11th February 2020 and at the RESTORE meeting in Berlin on the 17th February 2020.